Shilajit Benefits, Audited Trial by Trial

Shilajit has been tested in humans about eight times. The benefits of shilajit that people search for, more energy, better recovery, a slower clock, are mostly not among the things those eight trials measured. What was measured is narrow and specific: androgen levels in men aged 45 to 55, retention of maximal strength in young men after a fatiguing protocol, a blood marker of type 1 collagen synthesis, bone mineral density in postmenopausal women, skin blood flow, gene expression in muscle and skin, and time to bone union after a tibial fracture.

That is the honest answer, and it is not the answer the first page of results gives you. This page lists every one of those trials with its dose, its duration, its population, the extract it used and the arms that failed. It then names the outcomes people search for that no trial has ever looked at, because those absences are the most useful thing here. What shilajit is, geologically and chemically, is covered in our definition page. This one is about effect and evidence.

How to read a shilajit study before you read a shilajit claim

Most writing on this subject quotes a study without telling you what would have to be true for the study to mean anything. Six things decide that, and every trial below is described against all six.

Trial size. The largest shilajit trial published had 160 participants and was about bone union after surgery. The rest range from 25 to 75 people, split across two or three arms. A group of twenty is a signal generator, not a settled fact.

Population. Almost every trial recruited a narrow group: young recreationally active men, men aged 45 to 55, postmenopausal women with osteopenia, overweight adults. A result in one of those groups says nothing about anyone outside it, and the groups barely overlap.

Dose and duration. Published doses run from 250 mg to 1000 mg per day. Durations run from 28 days to 48 weeks. Two trials tested more than one dose, and in both the lower dose behaved differently from the higher one. A jar that gives you a different daily amount is not running the same experiment.

The material tested. This is the criterion nobody applies. Several of the human trials used one branded standardised extract, PrimaVie, and the systematic review discussed below assesses that product by name rather than shilajit in general. An extract standardised to a specification is not the same material as raw resin from an unnamed valley.

Who was involved. The 2016 muscle transcriptome study lists a co-author from Natreon India, the company behind that branded extract, among its authors. Independence is not a formality here, because the field is small enough that a handful of laboratories produced most of it.

What was not measured. Every trial has a much longer list of things it did not look at than things it did. That list is where almost all shilajit marketing lives.

Apply those six criteria and the picture changes shape. There is a real, small, mostly unreplicated evidence base, and there is a much larger set of claims sitting on top of it with nothing underneath.

Every human shilajit trial, and what each one actually measured

Trial	Population	Dose and duration	Measured	Result
Pandit et al. 2016, Andrologia	healthy men aged 45 to 55, India	250 mg twice daily, 90 days	total and free testosterone, DHEAS, LH, FSH	higher total testosterone, free testosterone and DHEAS against placebo
Keller et al. 2019, JISSN	63 recreationally active men, mean age 21	250 or 500 mg daily, 8 weeks	strength decline after a fatiguing protocol, serum hydroxyproline	500 mg differed from placebo in the upper half of the sample only; 250 mg did not differ from placebo
Neltner et al. 2024, J Diet Suppl	35 recreationally trained men, mean age 21	500 or 1000 mg daily, 8 weeks	serum pro-C1a1, a type 1 collagen marker	both doses rose from baseline; only the 1000 mg group beat placebo on the responder analysis
Pingali and Nutalapati 2022, Phytomedicine	60 postmenopausal women aged 45 to 65 with osteopenia	250 or 500 mg daily, 48 weeks	lumbar spine and femoral neck bone mineral density, bone turnover, MDA, GSH, hsCRP	density fell in the placebo group and fell less in both supplemented groups
Das et al. 2016, J Med Food	overweight and class I obese adults	250 mg twice daily, 8 weeks plus 4 weeks with exercise	skeletal muscle gene expression, glucose, lipids, creatine kinase, myoglobin	17 matrix-related probe sets upregulated; no change in glucose, lipids, creatine kinase or myoglobin
Das et al. 2019, J Am Coll Nutr	healthy middle-aged women	125 or 250 mg twice daily, 14 weeks	skin gene expression, skin microperfusion	perfusion higher than baseline and placebo at the higher dose only
Sadeghi et al. 2020, J Altern Complement Med	160 adults aged 18 to 60 after tibial shaft surgery, Iran	1000 mg daily, 28 days	time to radiographic bone union	mean 129 days against 153 days on placebo
Yadav et al. 2026, Cureus	25 healthy men aged 21 to 55, India	500 mg resin daily, 28 days	strength, endurance, VO2 max, fatigue score, CRP, liver and kidney panels	within-group improvements reported, but open-label and single-arm with no placebo

The androgen trial, and what a systematic review made of it

Pandit and colleagues (2016) ran a randomised, double-blind, placebo-controlled study at a state Ayurvedic college in Kolkata. Healthy volunteers aged 45 to 55 took 250 mg of purified shilajit twice daily for 90 consecutive days. Total testosterone, free testosterone and DHEAS were higher than placebo, and the gonadotropic hormones LH and FSH were maintained.

That trial is the load-bearing citation under most of what is written about shilajit benefits for men, and it carries more weight than it can hold. A 2024 systematic review in the International Journal of Impotence Research screened two decades of literature on 27 marketed testosterone boosters across 52 studies. Its conclusion was that most fail to raise total testosterone at all. Purified shilajit extract was among the few it rated possibly effective, and in one population only: men with late-onset hypogonadism. Not athletes. Not healthy young men. The men-specific evidence, including who that population actually is, belongs to our article on shilajit for men.

The strength trial, including the arm that did nothing

Keller and colleagues (2019) gave 63 recreationally active men, mean age 21, either 250 mg per day, 500 mg per day or placebo for eight weeks, then ran them through 100 maximal leg extensions. The finding that gets quoted is that the 500 mg group lost less maximal voluntary isometric strength after the fatiguing protocol, and had lower baseline serum hydroxyproline.

The finding that does not get quoted is the shape of it. The difference appeared in the upper half of the sample once the groups were split at the median, not in the groups as a whole, and the 250 mg arm was statistically indistinguishable from placebo. A trial in which the lower dose does nothing and the higher dose separates in half the sample is a reason to run a bigger trial, not a reason to buy anything. Nobody has run the bigger trial.

Collagen, skin and connective tissue

Three studies point the same direction using different instruments. Das and colleagues (2016) took muscle biopsies from overweight adults after eight weeks at 500 mg per day and found seventeen extracellular matrix probe sets upregulated. The same group (2019) took skin biopsies from healthy middle-aged women over fourteen weeks and reported higher skin microperfusion at the higher dose. Neltner and colleagues (2024) measured serum pro-C1a1, a circulating marker of type 1 collagen synthesis, and found it higher after eight weeks at 500 and 1000 mg per day.

Read that carefully. Three studies measured molecules, one measured blood flow in skin, and none measured how anyone looked, felt or performed in daily life. Gene expression sits upstream of an outcome. It is not an outcome.

What the trials in women measured

Two women-only studies exist, and the benefits of shilajit for women rest on those two and nothing else. Pingali and Nutalapati (2022) randomised 60 postmenopausal women aged 45 to 65 with osteopenia to placebo, 250 mg or 500 mg of a standardised aqueous shilajit extract daily for 48 weeks. Bone mineral density at the lumbar spine and femoral neck fell in the placebo group over the year and fell less in both supplemented groups, with bone turnover markers, malondialdehyde, glutathione and hsCRP moving in step. At 48 weeks it is the longest shilajit trial published, and it is still 60 people at one centre.

The second is the skin study above. Neither recruited premenopausal women, and no trial has looked at menstrual cycles, menopause symptoms or iron status in females of any age. Because the resin is iron-bearing, iron is the part that matters most in practice, and it is covered in our article on shilajit for women.

What people search for that no trial has measured

Body weight and body composition. No trial of shilajit on its own has measured either. The nearest thing is a 2025 randomised trial from Texas A&M in 166 adults with metabolic syndrome risk factors, in which shilajit appeared at 6 to 12 mg inside a chromium and amla formula while every participant trained three days a week and cut energy intake. Whatever that trial shows, it cannot separate a 6 mg ingredient from a supervised exercise programme. Anyone selling shilajit for a slimmer body is selling a trial that does not exist.

Cognition in healthy people. A 2012 review in the International Journal of Alzheimer’s Disease proposed a mechanism, that fulvic acid interferes with tau self-aggregation, and called for clinical trials. Fourteen years later there is still no adequately powered trial of shilajit on memory or attention in healthy adults. A mechanism is a hypothesis with a diagram attached.

Ageing. Nothing published measures ageing. The closest human data are gene expression in muscle and skin, plus one measurement of skin blood flow. If a page tells you the resin turns back a clock, ask which trial, in whom, over how long, and watch the answer disappear.

Energy as a felt experience. This is the most searched effect and the least studied one. The 28-day open-label pilot in 25 men reported a lower score on the Fatigue Severity Scale, but with no placebo arm and no blinding, a fatigue questionnaire measures expectation as much as anything else. Onset and timing are handled in how long shilajit takes to work.

Is shilajit good for the liver?

The liver question sits in the People Also Ask box in three languages and is answered by almost nobody, so here it is plainly: there is no human evidence either way, because no trial has recruited people with liver disease or tested liver outcomes as a primary endpoint.

Three things are known. A 2026 study in the Journal of Ethnopharmacology gave Tibetan shilajit extract to mice by gavage at 0.4 to 1.6 g per kg before a paracetamol challenge and reported lower plasma ALT and AST alongside changes in inflammatory and apoptotic signalling. That is a rodent model at doses far above any human serving, and it does not transfer. Second, the 28-day human pilot ran liver and kidney panels and reported all values within normal limits, in 25 men, with no control group. Third, and most usefully: the realistic liver risk from shilajit is not the resin, it is what unpurified resin carries. A 2025 analysis in BMC Chemistry quantified thallium at up to 0.5 micrograms per gram in commercial shilajit supplements, in some cases higher than in the crude material they came from. That is a purity question, and it is the article we would read first.

If you take prescribed medication metabolised by the liver, or you have any diagnosed liver condition, this is a question for your doctor or pharmacist and not for a shop.

What the material is, and why mineral-rich is a weak selling point

Shilajit is largely humic material with fulvic acid as its most discussed fraction, plus whatever the surrounding rock contributed. A 2026 analysis in the Journal of Trace Element Medicine and Biology ran twelve samples from different origins through ICP-MS and found wide variability in calcium and magnesium, in iron, zinc and manganese, and in the toxic elements, with rare earth patterns matching natural geochemistry rather than adulteration. Most metals travelled as low molecular weight complexes under 10 kDa.

Two consequences follow. Composition varies by origin, so two honest jars genuinely differ, which is why the label matters more than the mountain range printed on it. And the trace mineral content is real but small: this is not a substitute for a varied diet, and no European authorisation exists for a mineral claim on it. What a fulvic acid percentage on a label does and does not tell you is covered in fulvic acid benefits.

What is not established, and who should not take it

The evidence base is eight small trials, several using one branded extract, few replicated, and only one running as long as a year. Nothing here establishes that shilajit acts on any disease, and under Regulation (EC) 1924/2006 no health claim for shilajit is authorised in the EU, so a page telling you it acts on a condition is making a claim it is not permitted to make. Use that as a filter: the more confident the promise, the less likely the seller has read the literature.

The specific exclusions are not decoration.

Pregnancy and breastfeeding. Avoid. A 2018 case report in Gynecological Endocrinology describes a 37-year-old pregnant woman with persistent hypertension and low potassium after six months of mumijo, diagnosed as a licorice-like pseudohyperaldosteronism that resolved when she stopped taking it. One case is one case, and it is one more than any trial in pregnancy.

Iron-overload conditions. Shilajit is iron-bearing, as the elemental analysis above confirms. Anyone with haemochromatosis or another iron-overload diagnosis should not take it.

Prescribed medication. No interaction studies exist. Speak to a doctor or pharmacist first, particularly with anything affecting potassium, blood sugar or the liver.

Children. Not tested. Not for them.

Allergy and mast cell conditions. A 2019 case report in World Journal of Clinical Cases describes exercise-induced anaphylaxis in a 43-year-old woman in which shilajit was implicated as a cofactor, in the context of a suspected mast cell activation syndrome.

Mild digestive discomfort is the most common complaint across the trials, and the full picture is in shilajit side effects.

So is it worth taking?

Three things decide it, and none of them is a benefits list. First, whether the outcomes that were genuinely measured are outcomes you care about, because they are narrow and they may not include yours. Second, whether you can accept a field where the most relevant trial had 60 to 75 people and the lower dose sometimes did nothing. Third, and most concretely, whether the jar in front of you has been purified and tested, because the contamination literature is stronger and more consistent than the efficacy literature, and a contaminated jar makes every other question irrelevant.

If the honest version is enough for you, what matters next is the material itself. Our shilajit resin is sold with that order of priorities: purity first, evidence stated as evidence, no promise attached. If you are still choosing between formats rather than deciding whether to buy at all, resin against capsules is the next page, and how to spot real shilajit is the one to read if a jar is already on your shelf.